Group 1 - The core product of the company, Isupreglutide α, has received acceptance for a new veterinary drug clinical trial application for treating pet diabetes by the Ministry of Agriculture and Rural Affairs, with Phase I clinical trials expected to start in Q1 2026 [1] - Following the announcement, the company's stock price saw a significant increase, with a reported rise of 2.83% over the last five trading days as of February 13, 2026, closing at 27.60 HKD [1] - Despite the recent uptick, the stock has experienced a decline of 10.91% over the past 20 trading days, indicating volatility in its performance [1] Group 2 - Recent trading activity shows fluctuations in southbound capital, with a single-day reduction of 20,140 shares on February 10, 2026, and a total net reduction of 85,200 shares over the last five trading days [1] - However, there has been an overall net increase of 168,100 shares held over the past 20 trading days, with current holdings at 3,060,800 shares, representing 0.72% of the issued ordinary shares [1] - On February 13, 2026, there was a total net inflow of 529,140 HKD, indicating active participation from retail investors [1]
银诺医药宠物糖尿病新药临床试验申请获受理
Jing Ji Guan Cha Wang·2026-02-13 10:00